If the person with LGIB is on low-dose aspirin for prevention of a first heart attack (i.e., the person has never had a heart attack before), stopping the aspirin is recommended. In contrast, if the person has previously had a heart attack, the aspirin should be continued despite the active LGIB due to the benefits of preventing another heart attack and consequent death outweighing the risk of bleeding. Dual antiplatelet therapy (e.g., use of both aspirin and clopidogrel) should continue if the person with a LGIB underwent stenting of the heart's coronary arteries within the last 30 days or a recent acute coronary syndrome episode (e.g., unstable angina or a myocardial infarction) within 90 days of the LGIB event. Individuals at high risk of another heart attack but not meeting the above criteria should continue their aspirin during the LGIB event but stop the other antiplatelet medication for 1–7 days following cessation of the bleed.